Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Timothy M. Fernandes"'
Autor:
Mona Alotaibi, Jenny Z. Yang, Demosthenes G. Papamatheakis, W. Cameron McGuire, Timothy M. Fernandes, Timothy A. Morris
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Cardiac dysfunction from pulmonary vascular disease causes characteristic findings on cardiopulmonary exercise testing (CPET). We tested the accuracy of CPET for detecting inadequate stroke volume (SV) augmentation during exercise
Externí odkaz:
https://doaj.org/article/b4ec8aa08b0f4276bcd420cff27e8822
Autor:
Emanuel A. Keiler, Kim M. Kerr, David S. Poch, Jenny Z. Yang, Demosthenes G. Papamatheakis, Mona Alotaibi, Angela Bautista, Victor G. Pretorius, Michael M. Madani, Nick H. Kim, Timothy M. Fernandes
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract Current predictors of clinical outcomes after pulmonary thromboendarterectomy (PTE) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) are largely limited to preoperative clinical characteristics. N‐terminal‐pro‐bra
Externí odkaz:
https://doaj.org/article/5ec74f813f3045e987f9b2a069687eed
Autor:
Ina Jeong, Mona Alotaibi, Timothy M. Fernandes, Suhyun Kim, Kim M. Kerr, Jenny Yang, Victor Pretorius, Michael Madani, Nick H. Kim
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Patients with chronic thromboembolic pulmonary hypertension (CTEPH) require lifelong anticoagulant therapy. The safety and efficacy of direct oral anticoagulant (DOAC) in the chronic and transitional management of CTEPH has not been investig
Externí odkaz:
https://doaj.org/article/7e01dd920b434d6b8b98fcba640d19d0
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-3 (2021)
Drug‐induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib is a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse
Externí odkaz:
https://doaj.org/article/7556e2514dec401cbf21034982b444f7
Autor:
Jenny Z. Yang, Mazen F. Odish, Hannah Mathers, Nicole Pebley, Gabriel Wardi, Demosthenes G. Papamatheakis, David S. Poch, Nick H. Kim, Timothy M. Fernandes, Rebecca E. Sell
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Over the past 20 years, despite significant advancements in pulmonary arterial hypertension (PAH) medical therapy, many patients require admission to the hospital and are at risk for in‐hospital cardiac arrest (IHCA). Prior data found poor
Externí odkaz:
https://doaj.org/article/a57250a4047441f3a07df00ab371b6aa
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Although pulmonary endarterectomy (PEA) is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), many patients have inoperable disease, and some have persistent or recurrent pulmonary hypertension (PH) after surgery. Alte
Externí odkaz:
https://doaj.org/article/47fdc77d2ba942b289a850523809d7b5
Autor:
Nicolas Gallastegui MD, Jenny Y. Zhou MD, Annette von Drygalski MD, PharmD, RMSK, Richard F. W. Barnes PhD, Timothy M. Fernandes MD, MPH, Timothy A. Morris MD, FCCP
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Introduction: Acute respiratory illnesses from COVID19 infection are increasing globally. Reports from earlier in the pandemic suggested that patients hospitalized for COVID19 are at particularly high risk for pulmonary embolism (PE). To estimate the
Externí odkaz:
https://doaj.org/article/fc8d72a551234263934288bdfa2ea5c0
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/b6ef5d268dbe4638ab982eda96477716
Publikováno v:
Chest. 163:933-941
Publikováno v:
Nutrition in Clinical Practice. 37:1059-1073
The purpose of this review article is to provide a comprehensive review of iron deficiency in the setting of pulmonary arterial hypertension (PAH) and to evaluate the utility of iron supplementation in PAH. Iron deficiency is present in 33%-46% of pa